Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies

Fig. 3

Immunofluorescence staining of CK19, galectin-3, BRAFV600E, and Ki-67 on PTC organoids and the parental tumors. Passage numbers of PTC organoid lines were: PTC-1_O, P3; PTC-2_O, P3; PTC-3_O, P2; PTC-4_O, P4; PTC-5_O, P3; PTC-6_O, P2; PTC-7_O, P4; PTC-8_O, P3; PTC-9_O, P4. PTC, papillary thyroid cancer. T, parental tumor; O, organoid. Scale bar, 100 µm

Back to article page